Add-Aspirin
An inexpensive drug with a potential therapeutic role
The Add-Aspirin trial is investigating whether regular aspirin use after curative treatment for early stage common solid tumours can prevent tumour recurrence and prolong survival. Add-Aspirin includes participants with breast, colorectal, gastro-oesophageal and prostate tumours which, together, accounted for approximately one third of all cancer cases and cancer deaths in 2012.
As an inexpensive drug with a potential therapeutic role in several common cancers, aspirin could have a huge impact on the global cancer burden particularly given the increasing cancer incidence in lower resource countries.
Add-Aspirin recruits patients in the UK, Ireland and India.